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The effects of discontinuation of aluminum exposure on alumi-
num—induced osteomalacia. Studies in patients on dialysis have shown
that aluminum (Al) accumulation in bone plays a major role in the
pathogenesis of osteomalacia. It has been suggested that deferoxamine
(DFO) may be beneficial in the treatment of aluminum—induced
osteomalacia. The present studies were performed in four groups of
uremic rats to determine if DFO and/or discontinuation of Al adminis-
tration have an effect on bone histomorphometry and blood chemis-
tries. The groups were: 1) uremic control 2) aluminum (0.75 to 1.0
mg/rat i.p., five times a week for twelve weeks): 3) aluminum + DFO,
after twelve weeks Al was discontinued and the rats received DFO (75
mg/rat two times a week for nine weeks); 4) aluminum + time, after
twelve weeks Al was discontinued and the rats were sacrificed after
nine weeks. High levels of Al in serum and bone and low levels of PTH
were seen in rats receiving Al. Bone histology revealed Al at the
mineralization front, abnormal tetracycline uptake, and an increase in
osteoid. DFO treatment did not significantly change the level of Al in
bone, however both DFO treatment and discontinuation of Al reversed
towards normal the above described lesions. In conclusion, these
studies suggest that DFO and/or discontinuation of Al administration to
rats with approximately 30% of renal function greatly improve
aluminum—induced osteomalacia.
There is strong evidence to suggest that aluminum accumu-
lation in bone plays a major role in the pathogenesis of
osteomalacia in some patients on maintenance hemodialysis
[1—81. Previous studies have shown that aluminum in hone is
localized at the mineralization front [3, 7, 9, 101 and is associ-
ated with impaired mineralization [10]. Not only is aluminum in
bone increased in patients on hemodialysis [11, 121, but it has
been shown that the amount of osteoid present correlates
positively with the aluminum content of bone [9]. Aluminum
accretion during hemodialysis with impure water as well as
aluminum ingested as phosphate binding antacids appear to be
the main sources of aluminum accumulation in the bone of these
patients [13, 14].
It has been suggested that deferoxamine (DFO), a drug used
in the treatment of patients with iron intoxication, may be
beneficial in the treatment of aluminum—induced osteomalacia
[15—17], While the exact mechanism of this effect is unknown, it
is assumed that DFO chelates the aluminum from tissues and
the aluminum is then removed during dialysis. The present
studies were performed to gain further insight into the role of
aluminum in the development of osteomalacia, and to deter-
mine if DFO and/or simple discontinuation of aluminum admin-




Female Sprague—Dawley rats weighing from 225 to 250 grams
were subjected to 5/6 nephrectomy. After two weeks to allow
for recovery from surgery, the rats were randomly divided into
four groups which are depicted in Table 1. The first group
served as controls. The other three groups were given
intraperitoneal injections of aluminum chloride five times a
week for twelve weeks, at a dose of 3 mg of elemental aluminum
per kg body weight for the first five weeks and 4 mg/kg body
weight for the next seven weeks, The control group and Group
2, the aluminum group, were both killed after twelve weeks of
observation. The third group, aluminum + DFO, received
aluminum for twelve weeks followed by treatment with DFO
(Desferal, Ciba—Geigy, Summit, New Jersey, USA) intraperi-
toneally at a dose of 75 mg/kg body weight, two times a week
for nine weeks. In the fourth group, aluminum + time, alumi-
num was discontinued, and after 12 weeks the rats were
observed for a further nine weeks before sacrifice. All animals
were maintained on Purina rat chow (Rodent Laboratory Chow
p5001, Ralston—Purina Co., St. Louis, Missouri) and tap water
ad libitum.
The rats were given two doses of tetracycline hydrochloride
intraperitoneally at a dose of 50 mg/kg body weight (Acromy-
ci Lederle Laboratories Division, Pearl River, New York,
USA) fifteen days apart, with the last dose given three days
before sacrifice [181. At the time of sacrifice, blood was col-
lected from the aorta for chemical and immunoreactive para-
thyroid hormone (iPTH) determinations.
Biochemical determinations
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Calcium and magnesium were measured by atomic absorp-
tion spectrophotometry (Perkin—Elmer, Model 503, Norwalk,
Connecticut, USA). Phosphorus, creatinine, and BUN were
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Table 1. Study Groups
No. Group N Treatment
1 Control 4 twelve weeks, no treatment
2 Aluminum 7 twelve weeks, aluminum
3 Aluminum + 8 twelve weeks, aluminum +
DFO nine weeks DFO
4 Aluminum + time 11 twelve weeks, aluminum +
nine weeks no treatment
In alI four groups chronic renal failure was induced first.
determined with a Technicon autoanalyzer (model II, Techni-
con Instruments, Tarrytown, New York, USA). Aluminum was
determined by flameless atomic absorption spectrophotometry
(graphite furnace model HGA-400, Perkin—Elmer) [19]. Plasma
iPTFI was determined using chicken All, an antibody directed
towards the carboxy terminal region of the PTII molecule [20].
Measurement of bone mineral content
The femur was cleaned of marrow, ashed in a lab heat muffle
oven (Blue M Electric Company, Blue Island, Illinois, IJSA)
dissolved in concentrated hydrochloric acid and analyzed for
calcium, magnesium, phosphorus and aluminum.
Bone histology
At the time of sacrifice, the proximal portion of the tibia was
obtained and placed in Millonigs fixative for 24 hous. After
dehydration in acetone, the bones were embedded in methyl
methacrylate. All sections were cut using a Jung K microtome.
Histomorphometry was performed in 5 sections with modified
Masson Trichrome stain [211 and Aluminon stain (Fisher Sci-
entific, St. Louis, Missouri) [22]. Ten runstained sections were
used to assess tetracycline fluorescence. All histomorphometric
quantitations were done using Osteoplan image Analysis (hard-
ware, Carl Zeiss Inc., FRG, software, HH Malluche, Lexing-
ton, Kentucky, USA).
Statistical analysis was done using analysis of variance.
Results
Blood chemistries
Plasma chemistries are shown on Table 2. Plasma BUN and
creatinine levels were not significantly different in all groups.
There was also no significant difference in total calcium or
phosphorus levels among all four groups. ihe plasma aluminum
level in the control group was 18.8 3.9 rg/1iter. As expected,
the aluminum levels were significantly higher in the aluminum
group after twelve weeks of aluminum exposure 513.1 42.3
xg/1 (P > 0.01). Nine weeks after aluminum treatment had been
stopped, there was a significant decrease in plasma aluminum
levels (P > 0.01) in both the aluminum + DFO group (132 7.8
g/liter) and the aluminum + time group (129.0 15.1 rg/liter).
The iPTH level in the control group was 120,0 28.5
dEq/ml. iPTH levels were significantly lower in the aluminum
group after twelve weeks of aluminum exposure (55.3 5.8
pJEqIml, P> 0.05). iPTH levels were not different from control
values in either the aluminum + DFO group (109.1 13.5
dEq/ml) or in the aluminum + time group (94.4 13.9).
Bone mineral content
Bone mineral content in the four groups of rats are shown in
Table 3. Bone content of calcium, magnesium, and phosphorus
did not differ among the four groups of animals, There was also
no significant difference in bone aluminum content between the
three groups receiving aluminum. Twelve weeks of aluminum
exposure resulted in an increase in bone aluminum from 13.2
2.0 jxg/g of bone in the control group to 181.9 38.9 in the
aluminum group (P > 0.01). Bone aluminum content was not
significantly different from the aluminum group nine weeks after
aluminum exposure was discontinued whether or not animals
were treated with DF'O, Bone aluminum content was 162.2
6.5 /Lg/g of bone in the aluminum + DFO group and 164.6 4.7
in the aluminum + time group.
Bone histomorphometry
For histomorphometric analyses (Table 4), four parameters
of bone histology were compared: 1) the % relative osteoid
volume (the amount of osteoid [unmineralized bone matrix]
expressed as a % of total trabecular bone matrix); 2) the % total
osteoid surface (the % of the trabecular bone surface covered
by osteoid); 3) the mean osteoid seam width (the average width
of the osteoid seam); and 4) the width of the growth plate. As is
shown in Table 4, all four of these parameters were significantly
increased over control values in the aluminum animals. How-
ever, nine weeks after aluminum administration was discontin-
ued, all parameters returned to control values with or without
DFO treatment.
Figure IA shows sections of normal trabecular bone stained
with modified Masson Trichrome stain to distinguish mineral-
ized bone (M) from osteoid (0). There is almost no osteoid
present. Figure lB by comparison shows trabecular bone from
an animal in the aluminum group. Note the large amount of
osteoid present after twelve weeks of aluminum exposure.
Figure IC then shows an example of trabecular hone from an
animal in the aluminum + DFO group. After nine weeks of
treatment with DFO, the bone again looks like the control group
example, exhibiting little or no osteoid. This same result,
however, was seen also in the aluminum + time group (Table
4).
Figure 2 compares examples of three growth plates, Figure
2A from a Control animal, Figure 2B from an animal in the
aluminum group, and Figure 2C from an animal in the aluminum
+ DFO group. The average width of the growth plate in the
control animals was 0.16 0.01 microns. After twelve weeks of
aluminum exposure the average growth plate width had more
than doubled to 0.35 0.09 microns (P > 0.05). Again nine
weeks after aluminum treatment had been stopped, the width of
the growth plate returned to control values in both the alumi-
num + DFO group (0.15 0.01 microns) (P > 0.02) and the
aluminum + time (0.17 0.02) group (P > 0.05).
Tetracycline uptake is demonstrated in Figure 3. Figure 3A
shows an example from a control animal; tetracycline uptake is
seen at most surfaces as distinct double labels. After twelve
weeks of aluminum exposure, tetracycline uptake by the alu-
minum group, shown in Figure 3B, is spotty and diffuse, and
there is a total lack of double labels documenting that little or no
mineralization taking place. Figure 3C shows an example from
the aluminum + DFO group. The tetracycline uptake is seen
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Control N = 4
Aluminum N = 5
Aluminum + DFO N = 5
Aluminum + time N = 5
C Significance of difference from aluminum group P> 0.01.b Significance of difference from aluminum group P > 0.05.
Significance of difference from aluminum group P > 0,02.
again at most surfaces as are double labels, an indication that
mineralization is again occurring. Similar results were observed
in the aluminum + time group (Table 4).
Stainable aluminum is shown in Figure 4. In the aluminum
treated animals, Figure 4A aluminum as shown by aluminon
stain is localized at the mineralization front as well as on neutral
(non-osteoid covered) surfaces. The proportion of surfaces
showing stainable aluminum was significantly higher (P > 0.01)
in the aluminum group (56.9 4.0%) than both the aluminum +
DFO group (9.4 3.6%) shown in Figure 4B and the aluminum
+ time group (5.1 1.6%), shown in Figure 4C.
Discussion
These studies demonstrate that aluminum administration to
rats with a moderate degree of renal insufficiency results in
histological changes in bone consistent with osteomalacia, and
that discontinuation of aluminum will reverse these changes
towards normal whether or not DFO is given. After twelve
weeks of aluminum exposure, the aluminum treated animals
exhibited an increase in the percent relative osteoid, osteoid
seam width, and the width of the growth plate, as well as an
abnormal uptake of tetracycline with an absence of double
labeling, all indications of osteomalacia. Aluminum was found
localized in bone at the mineralization front as well as on
neutral surfaces. Nine weeks after aluminum administration
was discontinued, the extent of aluminum localized at the
mineralization front was markedly reduced. This was associ-
ated with a reduction in the percent relative osteoid, osteoid
seam width, and the return to normal of growth plate width.
Tetracycline uptake was improved, and double labels were
again seen documenting ongoing mineralization.
The bone aluminum content in the three groups of animals
which had received aluminum was comparable to values seen in
patients on long—term hemodialysis 6, 9, 10]. Total bone
aluminum content did not change in the aluminum + DFO or in
the aluminum + time animals, even though the percent of
surface showing stainable aluminum decreased from about 57%
to less than 10% nine weeks after aluminum exposure was
discontinued. These observations emphasize that it is the site of
aluminum accumulation (the mineralization front), rather than
the total bone aluminum content, which is important in the
pathogenesis of osteomalacia. Studies by Malluche et al 16] in
Table 2. Serum chemistries, aluminum and PTH in control and experimental groups
Group Cr BUN TCa P04 Mg Al PTH
mgldl j.gI1iter p.EqIml
Control N = 4 1.3 0.2 48.5 3.5 9.8 0.3 4.9 0.5 1.9 0.IC 18.8 3.9 120.0
Aluminum N = 7 1.1 0.1 41.5 2.2 9.5 0.1 4.8 0.3 2.0 0.la 513.1 42.3c 55.3 5.8
Aluminum + DFO N = 8 1.3 0.1 50.7 5.3 9.7 0.1 4.8 0.3 2.4 0.1 132.0 78de 109.1 l3.5
Aluminum + time N = 11 1.1 0.1 40.6 4.5 9.5 0.1 4.3 0.2 2.1 01b 129.0 15.l' 94.4 13.0
C Significance of difference from Aluminum + DFO group P> 0.02.
h Significance of difference from Aluminum + DFO group P> 0.05.
C Significance of difference from Control group P> 0.01.
d Significance of difference from Control group P > 0.02.
Significance of difference from Aluminum group P > 0.01.
Significance of difference from Aluminum group P> 0.05.
Table 3. Bone mineral content in control and experimental groups
Group Ca P04 Mg Al
mglg gIg
Control N = 4 242.3 25.4 119.7 7.8 4.7 0.3 13.2 2.0
Aluminum N 7 245.0 44.6 115.5 20.1 4.6 0.2 181.9 38.9k'
Aluminum + DFO N = 8 225.5 13.0 114.3 5.9 4.4 0.3 162.2 6.5
Aluminum + time N = 11 206.4 4.7 106.3 4.5 4.1 0.2 164.6 47C
a Significance of difference from control group P > 0.01
Table 4. Histomorphometric analysis on control and experimental animals
% Relative % Total Mean % Surface
osteoid osteoid osteoid Width of the picking up
Group volume surface seam width growth plate AL
3.8 0.7C 14.2 0.9 8.5 l.1C 0.16 0.01" 0.0 o.oa
30.4 7.6 33.6 10.2 19.0 4.1 0.35 0.09 56.9 4.0
2.1 0.5k' 6.1 l.5 11.9 1.1 0.15 0.Olc 9.4 3.6a
3.2 l.6a 11.6 41b 7.8 l.3' 0.17 0.02" 5.1 1.6k'
Deferoxainine and Al-induced osteomalacia 321
Fig. 1. Modified Masson Trichrorne stained sections qf Irabec u/ar
bone from the rat distinguishing mineralized bone (M), from steroid
(0). A shows a section from a control animal exhibiting no appreciable
ostcoid. B, by comparison shows a section from an Aluminum animal
exhibiting a significantly increased amount of osteoid, C shows a
section from an animal in the Aluminum + DFO group which looks
similar to the control section showing no appreciable amount of osteoid.
(x66)
Fig, 2, Modified Masson Trichrome stained sections of trabecular
bone from the rat comparing growth plate widths in an animaifrom the
control group (A) with an animal from the aluminum group (B). The
width of the growth plate in the aluminum group was more than twice
that of the control group (and the Aluminum + DFO group (C). (X66)
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Fig. 3. Comparison of tetracycline uptake in trabecular hone of the Fig. 4. Comparison of trahecular bone from rats showing stained
rat. A shows a control group animal with normal uptake and double aluminum. A depicts an animal from the aluminum group with alumi-
labels present. B shows an animal from the aluminum group exhibiting nurn seen at most surfaces. B from an Aluminum + DFO animal and C
spotty uptake and a total absence of double labels. C shows an from an aluminum + time animal, both show that 9 weeks after
Aluminum + DFO group animal demonstrating improved uptake of stoppage of aluminum exposure, very little aluminum is seen at sur-
tetracycline and the presence of double labels, (x66) faces. (x67)
uremic patients show a decrease in bone aluminum content time. It is also possible that rats would require more frequent or
after six—and—one—half to eight months of DFO treatment. Our much higher doses of DFO than given in this study to affect a
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The absence of a difference in results between the aluminum
1 DFO and the aluminum + time animals would raise the
question of the usefulness of DFO in the treatment of patients
with aluminum—induced osteomalacia. These data show that
with a sufficient amount of renal function, discontinuation of
aluminum alone may be sufficient in the reversal of osteomala-
cia. However, the situation may be different in patients without
significant renal function. For example, Kaeney et al [131 have
shown that no appreciable amount of aluminum is removed by
hemodialysis because aluminum is highly protein bound.
Hence, DFO has been used successfully to chelate aluminum
from tissues, resulting in a much higher serum aluminum
concentration and its subsequent removal by dialysis. Even in
peritoneal dialysis as much as 2200 g of aluminum (Siato-
polsky, Lewis—Finch, and Delmez, unpublished observations)
can be removed in one day. In transplanted patients, the use of
DFO could also substantially increase aluminum removal. The
mechanism by which aluminum induces osteomalacia is not
well defined although, the localization of aluminum at the
mineralization front suggests that it in some way interferes with
the calcification process. The mineralization front plays a key
role in the formation of bone, however, represents a small
component of the skeleton. This may explain why we did not
find a difference in bone mineral content between the normal
rats and the group with aluminum—induced osteomalacia. Se-
rum phosphorus levels were not decreased in the aluminum
group, indicating that hypophosphatemia was not a factor in the
development of aluminum—induced osteomalacia [231.
It has also been suggested that aluminum could interfere with
the metabolism of vitamin D causing or contributing to the
osteomalacia seen in the aluminum animals. Although
1,25(OH)2D levels were not measured in the present studies
this mechanism seems unlikely because in clinical observations,
dialysis osteomalacia fails to respond to I ,25(OH)2D3 treatment
[24, 251.
A decreased level of iPTH may be associated with decreased
bone turnover which would tend to minimize rather than
enhance osteoid accumulation. It has, however, also been
suggested that hyperparathyroidism may have a facilitative role
in the mineralization process in uremic patients [261. if this is
true, the decrease in iPTH seen in the aluminum group could
have contributed to their osteomalacia. Since in the aluminum
+ DFO and in the aluminum + time group not only was there a
significant decrease in serum aluminum, but also a remarkable
increase in the levels of i-PTH, these two factors may have
played a significant role in the improvement of the histomor-
phometric parameters observed in these two groups of rats.
The decrease in iPTH levels seen in this study are consistent
with observations seen in patients with aluminum induced
osteomalacia [3, 27]. This decrease could be due to the accu-
mulation of aluminum in the parathyroid glands which could
then inhibit the secretion of PTH. Cann, Prussin, and Gordan
[28] showed aluminum uptake by the parathyroid glands, and
studies by Morrissey et al [29, 301 in dispersed bovine parathy-
roid cells showed that aluminum inhibited the secretion of
parathyroid hormone. Recently Beilorin—Font and collabora-
tors [31] demonstrated in vivo studies with membranes from
normal bovine parathyroid glands, that aluminum in the me-
dium caused a progressive decrease in adenylate cyciase activ-
ity. Since adenylate cyclase activation is influenced by the
interaction of multiple sites within the adenylate cyclase com-
plex, the nature of the inhibition hy aluminum was explored by
examining the interaction of aluminum with substrate ATP and
magnesium, an allosteric activating metal ion, The data sug-
gests that the inhibition of parathyroid adenylase cyclase by
aluminum occurs at the level of the allosteric metal activating
site. These data provide a potential mechanism for the inhibi-
tion of PTH secretion by aluminum. Further studies are neces-
sary to fully understand all the potential mechanisms by which
aluminum suppresses PTH release.
In conclusion, the administration of aluminum to rats with
moderate renal insufficiency produces osteomalacia. Adminis-
tration of DFO and/or discontinuation of aluminum alone will
reverse these changes toward normal in rats with approximately
20 to 30% of renal function. These results raise the possibility
that in patients with GFR between 10 and 30 mI/mm, substitu-
tion of phosphate—binders containing aluminum by other bind-
ers (such as calcium carbonate) alone will significantly decrease
the amount of aluminum at the mineralization front and prevent
or reverse aluminum—induced osteomalacia. Obviously, further
studies in humans are necessary to prove this hypothesis.
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